Is tesofensine a peptide?

No. Tesofensine is a small molecule, not a peptide. It is included in research peptide catalogs due to overlapping interest in metabolic research, but its mechanism (triple monoamine reuptake inhibition) is entirely different from peptide-receptor signaling.

Which compound has stronger clinical trial data?

Tesofensine has Phase II clinical trial data showing 12.8% body weight reduction. AOD-9604 has preclinical and early clinical data plus FDA GRAS status as a food ingredient. Neither has full FDA pharmaceutical approval for weight management.

Are these products sold for therapeutic use?

No. Products discussed are for research, laboratory, and analytical use only.

Is tesofensine a peptide?

No. Tesofensine is a small molecule, not a peptide. It is included in research peptide catalogs due to overlapping interest in metabolic research, but its mechanism (triple monoamine reuptake inhibition) is entirely different from peptide-receptor signaling.

Which compound has stronger clinical trial data?

Tesofensine has Phase II clinical trial data showing 12.8% body weight reduction. AOD-9604 has preclinical and early clinical data plus FDA GRAS status as a food ingredient. Neither has full FDA pharmaceutical approval for weight management.

Are these products sold for therapeutic use?

No. Products discussed are for research, laboratory, and analytical use only.

AOD-9604 vs Tesofensine: Metabolic Research Comparison

AOD-9604 and tesofensine are both studied in metabolic research contexts, but they represent entirely different compound classes — a GH fragment peptide vs a small-molecule CNS reuptake inhibitor. This comparison covers mechanisms, clinical evidence, and research context.

AOD-9604 (GH Fragment)

Type: Modified HGH fragment (amino acids 177–191)
Mechanism: Beta-3 adrenergic fat oxidation without IGF-1 elevation
Delivery: Subcutaneous (peptide)
FDA status: GRAS as food ingredient (not pharmaceutical approval)
Key advantage: Lipolytic without growth-promoting or diabetogenic effects

Tesofensine (Small Molecule)

Type: Triple monoamine reuptake inhibitor (not a peptide)
Mechanism: Serotonin/norepinephrine/dopamine reuptake inhibition
Delivery: Oral capsule
Clinical data: Phase II — 12.8% body weight reduction
Key advantage: CNS-mediated appetite suppression + thermogenesis

Dimension	AOD-9604	Tesofensine
Compound class	Peptide (GH fragment)	Small molecule
Primary mechanism	Adipocyte beta-3 lipolysis	Triple monoamine reuptake inhibition
Delivery route	Subcutaneous	Oral capsule
GH / IGF-1 impact	No IGF-1 elevation	Not GH-related
Clinical stage	Preclinical + GRAS	Phase II completed
FDA approval	GRAS (food only)	Not approved

View AOD-9604 View Tesofensine Weight Research Hub

Frequently Asked Questions

AOD-9604 is a modified GH fragment (peptide) that acts on adipocyte beta-3 adrenergic pathways for lipolysis. Tesofensine is a small-molecule triple monoamine reuptake inhibitor (serotonin/norepinephrine/dopamine) that works through CNS-mediated appetite suppression. Fundamentally different compound classes and mechanisms.